To enhance the oversight of cannabis production under its regulatory mandate, the Cannabis Directorate sought expert support in developing a risk-based decision-making framework tailored to its compliance and enforcement responsibilities. The directorate aimed to better assess and respond to non-conformance with Good Production Practices (GPP) as defined in the Cannabis Act and Regulations, using a data-driven approach.

To support the refinement and implementation of its ecological risk guidance, a federal department responsible for marine conservation engaged expert assistance in risk communication. The primary objective was to ensure that the national guidance for ecological risk assessment—developed as part of the department’s marine spatial planning and marine protected areas initiatives—could be effectively communicated to diverse internal and external audiences.

To support more effective health policy and pandemic preparedness, this project examined how environmental health factors intersect with chronic disease and influence pandemic resilience. The client sought evidence to clarify how exposures to contaminants in air, water, and soil contribute to the environmental burden of disease in Canada and exacerbate vulnerability to infectious disease outcomes, including COVID-19.

To support more consistent and quantitative assessments of new micro-organisms under the Canadian Environmental Protection Act, Health Canada's New Substances Program (NSP) sought to refine the tools and processes within its Microbial Risk Assessment Framework (MRAF). The NSP had previously collaborated with RSI to review and modernize the MRAF and develop a supporting computational tool. However, further work was required to validate the tool and ensure it aligned with current program needs and regulatory expectations.

To support the evaluation of a new veterinary pharmaceutical product intended for use in bovines, a scientific review was requested of submitted toxicological data related to the active compound LY488756. This compound, proposed under the product name Experior, had been advanced for registration based on its claimed selective action on β3-adrenergic receptors and a lack of mutagenic, carcinogenic, or teratogenic effects. Given its potential entry into the human food supply via meat residues, an independent expert analysis of the submission was deemed necessary to determine its safety.

To support decision-making around modifications to opioid agonist treatment delivery, a detailed risk assessment was requested to evaluate the integration of secure dispensing devices for direct patient access to hydromorphone. Building on a previously conducted preliminary assessment, the work required a structured framework that would articulate hazards, assess likelihoods and risks, and identify mitigation strategies associated with introducing these devices into service delivery models.